drugset / Trial / NCT00182559
The Vienna Prograf and Endothelial Progenitor Cell Study
RandomizedParallel-groupOpen-labelBasic science
Summary
The aim of the study is to determine if the conversion from the immunosuppressive agent cyclosporine to tacrolimus contributes to an improvement of the cardiovascular risk factors, better kidney function and immune system.
Timeline
- Start
- 2004-04
- Primary completion
- 2009-05
- Completion
- 2009-05
Publications
- Plischke M, Riegersperger M, Dunkler D, Heinze G, Kikic Z, Winkelmayer WC, Sunder-Plassmann G. Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial. PLoS One. 2015 Aug 13;10(8):e0135674. doi: 10.1371/journal.pone.0135674. eCollection 2015.
- Riegersperger M, Plischke M, Steiner S, Seidinger D, Sengoelge G, Winkelmayer WC, Sunder-Plassmann G. Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. Transplantation. 2013 Jun 15;95(11):1338-45. doi: 10.1097/TP.0b013e31828fabb3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | — | — |
| Comparator | Tacrolimus | Small molecule | 0.1 mg/kg | — |